Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GCTK Stock Forecast 2025-2026
$0.09
Current Price
$3.03M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GCTK Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
GCTK Price Momentum
-35.7%
1 Week Change
-40.0%
1 Month Change
-99.8%
1 Year Change
-98.8%
Year-to-Date Change
-99.8%
From 52W High of $62.60
+2.2%
From 52W Low of $0.09
📊 TOP ANALYST CALLS
Did GCTK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GlucoTrack is one of their latest high-conviction picks.
Latest GCTK Stock Price Targets & Analyst Predictions
GCTK has shown a year-to-date change of -98.8% and a 1-year change of -99.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GCTK. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GCTK Analyst Ratings
0
Buy
0
Hold
0
Sell
GCTK Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.09
Latest GCTK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GCTK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Glucotrack Inc. (GCTK) Competitors
The following stocks are similar to GlucoTrack based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Glucotrack Inc. (GCTK) Financial Data
Glucotrack Inc. has a market capitalization of $3.03M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -694.3%.
Valuation Metrics
Market Cap
$3.03M
Enterprise Value
$-5,804,726
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+334.7%
Current Ratio
4.8x
Debt/Equity
3.6x
ROE
-694.3%
ROA
-161.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Glucotrack Inc. (GCTK) Business Model
About Glucotrack Inc.
What They Do
Develops non-invasive glucose monitoring technology.
Business Model
The company generates revenue by offering its innovative Glucotrack device, which allows individuals with diabetes to monitor their glucose levels non-invasively. This device targets both the healthcare and biotechnology markets, facilitating improved patient comfort and adherence to monitoring regimens.
Additional Information
Glucotrack Inc. is poised to disrupt the medtech industry by providing solutions that align with the growing demand for patient-centered healthcare. By reducing the need for painful finger-prick tests, it addresses both the physical and psychological challenges faced by diabetic patients, potentially increasing market adoption.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
11
CEO
Mr. Paul V. Goode Ph.D.
Country
United States
IPO Year
2013
Website
glucotrack.comGlucotrack Inc. (GCTK) Latest News & Analysis
Latest News
Quick Summary
Glucotrack, Inc. will implement a 1-for-60 reverse stock split effective June 16, 2025. The stock will continue trading on Nasdaq under the symbol "GCTK."
Why It Matters
A 1-for-60 reverse stock split can signal financial distress, potentially impacting liquidity and investor sentiment. It may also affect stock price and market perception of Glucotrack's viability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Glucotrack, Inc. (Nasdaq: GCTK) will present safety and performance data from its first-in-human trial of a next-generation continuous blood glucose monitoring system at an upcoming Innovation Hub poster session.
Why It Matters
Glucotrack's presentation on its innovative continuous glucose monitoring technology could signal advancements in diabetes management, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
18 days ago
Quick Summary
Glucotrack has appointed an experienced medical device executive to enhance its development of long-term implantable blood glucose monitoring technology.
Why It Matters
The addition of an experienced executive enhances Glucotrack's credibility and potential for innovation in a growing market, signaling possible future growth and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Patients are now involved in the development of long-term implantable continuous blood glucose monitoring technology, indicating a shift towards patient-centric healthcare innovations.
Why It Matters
Patient involvement in developing glucose monitoring technology can enhance product relevance and adoption, potentially driving growth for companies in the diabetes care market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A long-term feasibility study for a fully implantable continuous blood glucose monitor (CBGM) system is set to begin patient implants in Australia in Q3 2025.
Why It Matters
The upcoming feasibility study for a fully implantable glucose monitor indicates potential advancements in diabetes management, which could drive market growth and enhance investor interest in related healthcare stocks.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
1 month ago
Quick Summary
A successful first-in-human study has led to a significant advancement in long-term clinical evaluation, indicating progress in medical research and potential investment opportunities.
Why It Matters
Successful long-term clinical evaluations indicate potential for future product approvals, impacting company valuations and investment opportunities in biotech and healthcare sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GCTK Stock
What is Glucotrack Inc.'s (GCTK) stock forecast for 2025?
Analyst forecasts for Glucotrack Inc. (GCTK) are not currently available. The stock is trading at $0.09.
Is GCTK stock a good investment in 2025?
Analyst ratings for GCTK are not currently available. The stock is currently trading at $0.09. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GCTK stock?
Price predictions from Wall Street analysts for GCTK are not currently available. The stock is trading at $0.09.
What is Glucotrack Inc.'s business model?
The company generates revenue by offering its innovative Glucotrack device, which allows individuals with diabetes to monitor their glucose levels non-invasively. This device targets both the healthcare and biotechnology markets, facilitating improved patient comfort and adherence to monitoring regimens.
What is the highest forecasted price for GCTK Glucotrack Inc.?
Price targets from Wall Street analysts for GCTK are not currently available. The stock is trading at $0.09.
What is the lowest forecasted price for GCTK Glucotrack Inc.?
Price targets from Wall Street analysts for GCTK are not currently available. The stock is trading at $0.09.
What is the overall GCTK consensus from analysts for Glucotrack Inc.?
Analyst ratings for GCTK are not currently available. The stock is trading at $0.09.
How accurate are GCTK stock price projections?
Stock price projections, including those for Glucotrack Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2025 7:33 PM UTC